Heart Disease in Women: Where Are We Now and What is The Future?

Zaman, Sarah; Chow, Clara K; Lam, Carolyn S.P.; Saw, Jacqueline; Nicholls, Stephen J.; Figtree, Gemma A.

doi:10.1016/j.hlc.2020.11.001

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2021 has seen not just one but two special issues published: first, the Women’s Heart Health edition in January 2021 [ 56 ], and more recently, the Vascular Ageing edition [ 57 ], both linked to annual CSANZ Scientific meetings. The Women’s Heart Health edition has been freely available as the “sample issue” of Heart, Lung and Circulation for all of 2020; Geraghty et al.…”

Section: : Not Just Covid-19mentioning

confidence: 99%

Heart, Lung and Circulation in the COVID-19 Era: About COVID-19, Not Just About COVID-19

Gregory

Denniss

2021

Heart, Lung and Circulation

View full text Add to dashboard Cite

Section: : Not Just Covid-19mentioning

confidence: 99%

Heart, Lung and Circulation in the COVID-19 Era: About COVID-19, Not Just About COVID-19

Gregory

Denniss

2021

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…Adverse events following interventional therapy are common in patients with coronary heart disease, and it might result in secondary injuries. Multiple factors such as coronary atherosclerosis, decreased blood vessel elasticity, and insufficient blood supply to the heart are contributors coronary heart disease [1][2][3]. Commonly, interventional therapy is required for patients with severe conditions.…”

Section: Introductionmentioning

confidence: 99%

Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease

Shao¹,

Chen²

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the efficacy of clopidogrel combined with systemic management care in the prevention of adverse events in patients with coronary heart disease after interventional therapy.Methods: 100 patients undergoing interventional therapy after coronary heart disease admitted to Jinan Third People’s Hospital from April 2018 to April 2020 were assigned at a ratio of 1:1 either into control (low-molecular-weight heparin (LMWH) injection) or study groups randomly (clopidogrel plus system management care). Thrombin time, prothrombin time, fibrinogen, incidence of adverse events, NIHSS score and QLI score were determined for the two groups.Results: There thrombin time, prothrombin time and fibrinogen in the two groups were similar (p >0.05). The study group showed a significantly lower incidence of adverse events than the control group (p < 0.05). The treatment administered to the study group resulted in a higher QLI (quality of life) scores than those in the control group (p < 0.05). Remarkably lower National Institutes of Health Stroke Scale (NIHSS) score was reported in the study group versus control group (p < 0.05).Conclusion: Clopidogrel plus systemic management care might be a preferable therapeutic strategy for patients with coronary heart disease undergoing interventional therapy. It reduces the incidence of adverse events, significantly improves the quality of life of patients, and enhances neurological function. Thus, this therapeutic strategy has significant promise in the management of coronary heart disease.

show abstract

Heart Disease in Women: Where Are We Now and What is The Future?

Cited by 2 publications

References 30 publications

Heart, Lung and Circulation in the COVID-19 Era: About COVID-19, Not Just About COVID-19

Heart, Lung and Circulation in the COVID-19 Era: About COVID-19, Not Just About COVID-19

Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease

Contact Info

Product

Resources

About